Carcinoid Tumors After Failure of Somatostatin Analogs: a Randomized Phase III of Octreotide Lutate Peptid Receptor Radionuclide Therapy (PRRT) Versus Interferon alpha-2b

Trial Profile

Carcinoid Tumors After Failure of Somatostatin Analogs: a Randomized Phase III of Octreotide Lutate Peptid Receptor Radionuclide Therapy (PRRT) Versus Interferon alpha-2b

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 08 Jul 2016

At a glance

  • Drugs Lu-177 octreotide (Primary) ; Interferon alpha-2b
  • Indications Gastrointestinal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms CASTOR
  • Most Recent Events

    • 04 Apr 2016 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
    • 05 Jan 2015 Planned number of patients changed from 60 to 66 as reported by ClinicalTrials.gov record.
    • 05 Jan 2015 Planned initiation date changed from 1 Sep 2014 to 1 Mar 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top